AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 19th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Astrazeneca Plc, consider:
The company's compound free cash flow growth rate over the past 5.55 years comes in at -0.12%; that's greater than only 15.12% of US stocks we're applying DCF forecasting to.
Relative to other stocks in its sector (Healthcare), Astrazeneca Plc has a reliance on debt greater than 62.88% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Astrazeneca Plc? See PRGO, CPIX, RMD, ARA, and NRC.
The FDA approves AstraZeneca's (AZN) blood thinner Brilinta (ticagrelor), combined with aspirin, for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.The med was first approved in the U.S. in July 2011 for acute coronary syndrome....
The first wave of the COVID-19 pandemic may be waning. Scientists in Europe and the United States say the relative success of draconian lockdown and social distancing policies in some areas and countries means virus transmission rates may be at such low levels that there is not enough disease circulating to truly test potential vaccines.
AstraZeneca, now the most valuable London-listed company, has received international attention thanks to its hot pursuit of a coronavirus vaccine. It sealed U.S. government funding last month and aims to produce a billion doses this and next year. But while the recent buzz around the British firm has focused on a vaccine, cancer and heart medications are still its core business. On Monday (June 1) AstraZeneca clinched expanded regulatory backing for two medications, including one for major cancer treatment Lynparza. A panel of the European health regulator gave it the go ahead for use on a form of advanced pancreatic cancer. Also on Monday, the company got a green light from the U.S. for a heart medication. Meanwhile, AstraZeneca's covid vaccine manufacturing partner Oxford Biomedica l...
FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.